SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Sigyn Therapeutics, Inc.

Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025

$0.03+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $48.16K
P/E (TTM): –
Dividend yield: –

Sigyn Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	–	–	–	–	–	0.14	0.03	0.04	0.03	0.04
Cost of Revenue	–	–	–	–	–	0.04	0.01	0.02	0.01	0.03
Gross Profit	–	–	–	–	–	0.11	0.02	0.02	0.02	0.02
Research & Development	0.77	0.80	0.66	0.73	0.42	–	–	–	–	–
General & Administrative	1.74	1.66	1.49	1.27	0.50	0.61	0.86	1.05	0.83	0.40
Advertising Expenses	0.00	0.00	0.00	0	0.00	0.01	0.05	0.07	–	–
Operating Expenses	2.52	2.46	2.15	2.01	0.92	0.63	1.02	2.05	2.27	0.41
Operating Income	-2.52	-2.46	-2.15	-2.01	-0.92	-0.52	-1.00	-2.03	-2.25	-0.39
Interest Expense	–	–	–	0.03	0.34	0.06	0.35	0.79	-0.44	–
Other Non-Operating Income	-0.82	-1.69	-0.78	-1.00	-0.34	-2.80	-1.30	-1.82	0.44	–
Asset Impairment Charges	–	–	–	0.54	–	–	0.94	–	–	–
Pretax Income	-3.34	-4.15	-2.93	-3.00	-1.26	-3.31	-2.30	-3.84	-2.69	-0.39
Income Tax Expense	–	–	–	–	–	–	0.00	0.00	–	–
Income from Continuing Operations	–	–	–	–	–	-3.31	-2.31	-3.85	–	–
Income from Discontinued Operations	–	–	–	–	–	–	-0.31	-0.41	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	-3.07	-2.62	-4.25	–	–
Net Income	-3.34	-4.15	-2.93	-3.00	-1.26	-3.07	-2.62	-4.25	-2.69	-0.39
EPS (Basic)(per share)	-2.51	-3.77	-3.13	-0.08	-0.17	-6.00	-6.00	-13.50	-13.50	-1.50
EPS (Diluted)(per share)	-2.51	-3.77	-3.13	-0.08	-0.17	-6.00	-6.00	-13.50	-13.50	-1.50
Shares Outstanding (Basic, Weighted)(shares)	1.33	1.10	0.93	36	7.35	0.54	0.43	0.31	0.21	0.19
Shares Outstanding (Diluted, Weighted)(shares)	1.33	1.10	0.93	36	7.35	0.54	0.43	0.31	0.21	0.19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2024: 84.9%

Financial strength

Current ratio: 0.02
Debt to equity: -0.52
Debt to assets: 2278.2%
Cash to current liabilities: 2.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –